Dr. Undurti Narasimha Das is a world-renowned clinical immunologist and endocrinologist whose pioneering work has significantly advanced translational research in nutritional biochemistry and metabolic disorders. He currently serves as Founder President and Chief Executive Officer of UND Life Sciences, a biotechnology company he established in Ohio in 2004 that has since relocated to Washington state. Dr. Das also holds the dual position of Chief Medical Officer and Chairman of the Scientific Advisory Board at Asha Nutrition Sciences, Inc., where he provides strategic scientific direction for nutritional therapeutics development. His distinguished academic career spans over three decades, having previously served as Professor of Medicine at Nizam's Institute of Medical Sciences in Hyderabad from 1990 to 1996 and as Professor and Head of the Division of Internal Medicine at L.V. Prasad Eye Institute until 1999.
Dr. Das's groundbreaking research has profoundly impacted the understanding of essential fatty acids, particularly gamma-linolenic acid, in treating cancer, diabetes, and inflammatory conditions. His work revealed the tumoricidal properties of cis-unsaturated fatty acids and established gamma-linolenic acid's role in controlling glioma progression, leading to innovative approaches for brain tumor treatment. With over 500 research publications and 5 awarded patents including methods for selectively occluding blood supplies to neoplasias, his scientific contributions have had substantial clinical impact. Dr. Das developed novel drug delivery systems using liposomal, nano, and SiRNA technologies to target cancer and metabolic syndrome more effectively, creating new therapeutic pathways through his investigations of nutrient-disease interactions.
Beyond his research achievements, Dr. Das has significantly shaped his field through editorial leadership as Editor-in-Chief of Lipids in Health and Disease and Current Nutrition and Food Science, influential journals in nutritional biochemistry. He has mentored numerous doctoral students throughout his career and serves on multiple scientific advisory boards, bridging the gap between academic research and clinical applications. Dr. Das continues to drive innovation with current research focused on developing targeted therapies for obesity, cancer, diabetes, hypertension, and schizophrenia. His ongoing work seeks to further elucidate the role of long-chain polyunsaturated fatty acids in disease prevention, maintaining his position at the forefront of translational nutritional science with a commitment to transforming biochemical discoveries into practical clinical solutions.
